PAVmed Inc. (PAVM)

Nasdaq: PAVM · Surgical & Medical Instruments & Apparatus · New York, NY · filing with the SEC since 2014

Full chart Alerts Compare

Grade3.9

◀ Past 2.8● Present 5.1▶ Future 3.2

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of PAVmed Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.9/10

◀ Past2.830% of the headline

● Present5.140% of the headline

▶ Future3.230% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.8/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

1.9/10

Has it survived what it has been through?

15 warning events since 2017; the latest 2025-04-25.

weight 33% of this tense · 19th percentile among 121 sector filers · read for itself

From the record

PAVmed Inc.'s filings since 2017 show 15 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 7 times, the latest 2025-01-24); an auditor change (8-K item 4.01, 2 times, the latest 2025-04-25); a late-report notice (Form NT 10-K or NT 10-Q, 6 times, the latest 2022-04-01) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

2.1/10

What has it actually done, year after year?

-38.6% a year over 5 filed years; profitable in 2 of 5.

weight 45% of this tense · 21st percentile among 105 sector filers · read for its customers

From the record

PAVmed Inc.'s 5 filed years say what it did: revenue went from $500 thousand in fiscal 2021 to $71 thousand in fiscal 2025, down 38.6% a year; it rose in 2 of 4 years; the deepest fall was 98% from fiscal 2024 to fiscal 2025; net income was positive in 2 of 5 of those years (its annual reports).

What it rests on

revenue growth over the filed span-38.6%bottom 3% of its family
the share of years revenue rosebottom 12% of its family
the share of filed years with a profittop 35% of its family
the deepest fall from a revenue peak97.6%bottom 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

5.7/10

How has it treated the people who own it?

SI estimate 5.7/10, confidence 35 of 100 (one part).

weight 22% of this tense · 57th percentile among 120 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 43% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 120 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: PAVmed Inc.'s shareholder treatment is put at 5.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 43% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.1/1040% of the headline grade · 3 of 3 filed

Financial health

as filed

5.6/10

Is it financially healthy right now?

ROE 1%: 1¢ of profit per shareholder dollar. Leverage 12%: owes 12¢ per asset dollar.

weight 45% of this tense · 56th percentile among 120 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, PAVmed Inc. earned about 1 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned less than nothing, about minus 0 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 12 cents per dollar of assets (the filed statements).

What it rests on

what it owes per dollar of assetstop 6% of its family
return on equitytop 28% of its family
gross profit against assetsbottom 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

3.5/10

How strong is its position in its industry?

bottom 34% of 109 in its family; net margin 564.8%.

weight 33% of this tense · 34th percentile among 109 sector filers · read for its customers

From the record

PAVmed Inc.'s standing among 109 graded names in its industry family: revenue of $71 thousand in fiscal 2025 ranks in the bottom 1% by size; a net margin of 564.8% ranks in the top 1%; revenue growth of -42.7% a year over the last 3 filed years ranks in the bottom 3% (its annual reports).

What it rests on

revenue against the family$71,000bottom 1% of its family
net margin564.8%top 1% of its family
three-year revenue growth-42.7%bottom 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

6.4/10

What are the people in charge doing?

top 36% of 91 in its family for leadership; chief executive since 2016.

weight 22% of this tense · 64th percentile among 91 sector filers · read for its shareholders

From the record

PAVmed Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Aklog, Lishan (Chairman and CEO, as filed), filing under that title since 2016-01-29, 10.8 years (top 18% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 5.1 years (bottom 45%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (top 35%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge4 in three years among 10 peopletop 35% of its family
the median years the people in charge have filed5.1 yearsbottom 45% of its family
the chief executive's years on the record10.8 yearstop 18% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

3.2/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

3.5/10

How much room does it have to grow?

bottom 34% of 104 in its family for room to expand.

weight 45% of this tense · 34th percentile among 104 sector filers · read for itself

From the record

PAVmed Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $2 million against no long-term debt tagged leaves 4% of its assets as net cash, bottom 38% of its family; cash from operations less capital spending is -7376.1% of revenue (bottom 1%); a gross margin of -207% (bottom 1%); research spending of 6326.8% of revenue (top 2%) (its annual report).

What it rests on

cash less debt against assets4.0%bottom 38% of its family
cash from operations less capital spending against revenue-7376.1%bottom 1% of its family
gross margin-207.0%bottom 1% of its family
research spending against revenue6326.8%top 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

1.1/10

What could actually drive growth from here?

bottom 11% of 105 in its family for growth drivers.

weight 33% of this tense · 11th percentile among 105 sector filers · read for its customers

From the record

PAVmed Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -42.7% a year over the last three filed years against -38.6% over all 5, slowing (bottom 39% of its family); the newest year grew -97.6% (bottom 1%); research spending grew -43.8% a year (bottom 2%); capital spending grew -72.8% a year (bottom 3%) (its annual reports). PAVmed Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-4.1 points a yearbottom 39% of its family
the newest year's revenue growth-97.6%bottom 1% of its family
three-year growth of research spending-43.8%bottom 2% of its family
three-year growth of capital spending-72.8%bottom 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

6.0/10

Did its newest year beat what its own record pointed to?

top 40% of 88 in its family for expectations against reality.

weight 22% of this tense · 60th percentile among 88 sector filers · read for its shareholders

From the record

PAVmed Inc.'s newest year against its own record: revenue of $71 thousand in fiscal 2025 came in 99.2% below the $8 million its prior three years' pace pointed to (bottom 1% of its family); net income of $401 thousand against a prior three-year average of $38 million (top 18%); a net margin of more than its whole revenue against losses larger than its revenue before (top 2%) (its annual reports).

What it rests on

revenue against the prior three years' pace-99.2%bottom 1% of its family
net income against the prior three years' average+101%top 18% of its family
net margin against its prior averageup more than 100 pointstop 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton PAVM · research, not advice